Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546793 · ClinicalTrials.gov registry record · Phase 1
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00546793 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 32 participants.
The verdict
NCT00546793, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when administered intravenously.
Interventions
- BIOLOGICAL veltuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546793
The ClinicalTrials.gov registry entry for NCT00546793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which veltuzumab is the first listed.
NCT00546793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00546793 about?
NCT00546793 is a clinical study titled "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL". The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when administered intravenously.
What is the current status of trial NCT00546793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-01. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00546793?
The interventions under investigation include: veltuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00546793?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.